Literature DB >> 8432516

The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine-labeling index: a study of metastatic tumors of the brain.

W A Mourad1, J H Connelly, D L Sembera, E N Atkinson, J M Bruner.   

Abstract

Bromodeoxyuridine (BrdU) is a thymidine analog that is incorporated into cellular DNA in the synthetic phase. The BrdU-labeling index (BLI) thus reflects the S-phase fraction. The argyrophilic nucleolar organizer regions (AgNORs) are silver-stained granules that have been correlated with ploidy and/or S-phase fraction. Two AgNOR counting methods have been proposed to distinguish between ploidy and S-phase fraction: the mean AgNOR (mAgNOR) count (the mean number of AgNOR granules in 100 cells), which is believed to reflect ploidy, and the AgNOR proliferative index (pAgNOR) (the percentage of cells exhibiting five or more AgNOR granules per nucleus), which is believed to reflect S-phase fraction. To evaluate the latter hypothesis we studied 19 tumors metastatic to the brain in patients who had received preoperative low-dose BrdU injections. Formalin-fixed, paraffin-embedded sections of the resected tumors were stained using the indirect immunoperoxidase technique and a monoclonal antibody to BrdU. The BLI was determined by counting 1,000 tumor cells in each case; AgNOR silver staining was performed on sections of the same blocks studied for BLI. The correlation between pAgNOR counts and BLI was statistically significant (r = .649, P = .003). No statistically significant correlation could be obtained between mAgNOR counts and BLI (r = .421, P = .17). We conclude that the pAgNOR count can reliably reflect the proliferative activity of cells. The method can prove beneficial in situations in which cell kinetic analysis is needed and in which invasive procedures, such as BrdU injection, are not feasible or are contraindicated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432516     DOI: 10.1016/0046-8177(93)90302-w

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Modified method of AgNOR staining for tissue and interpretation in histopathology.

Authors:  Mulazim Hussain Bukhari; Shahida Niazi; Saeed Akhter Khan; Ihsanulla Hashmi; Shahida Perveen; Shahzad Shafqat Qureshi; Naseer Ahmed Chaudhry; G R Qureshi; Mumtaz Hasan
Journal:  Int J Exp Pathol       Date:  2007-02       Impact factor: 1.925

Review 2.  Nucleolar adaptation in human cancer.

Authors:  Leonard B Maggi; Jason D Weber
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

3.  Demonstration of silver-stained nucleolar organizer region associated proteins (AgNORs) after wet autoclave pretreatment in breast carcinoma: correlation to tumor stage and long-term survival.

Authors:  D Ofner; B Bier; S Heinrichs; M Berghorn; M Dünser; H A Hagemann; D Langer; W Böcker; K W Schmid
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.

Authors:  M Borzio; D Trerè; F Borzio; A R Ferrari; S Bruno; M Roncalli; G Colloredo; G Leandro; F Oliveri; M Derenzini
Journal:  Mol Pathol       Date:  1998-04

5.  Validation of silver-stained nucleolar organizer regions for evaluation of invasive character of urinary bladder carcinoma in rats and mice.

Authors:  H Iwata; T Otoshi; N Takada; T Murai; S Tamano; T Watanabe; Y Katsura; S Fukushima
Journal:  Urol Res       Date:  1995

6.  Argyrophilic nucleolar organizer regions. A revised version of the Ag-NOR-staining technique.

Authors:  Q Li; G W Hacker; G Danscher; U Sonnleitner-Wittauer; L Grimelius
Journal:  Histochem Cell Biol       Date:  1995-08       Impact factor: 4.304

7.  Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas.

Authors:  X Xie; O P Clausen; P De Angelis; M Boysen
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.